PULIKE(SH:603566) Shang Hai Zheng Quan Bao·2025-04-11 20:47Core Viewpoint - The announcement highlights that the company's subsidiary, Luoyang Huizhong Veterinary Medicine Co., Ltd., has received a new veterinary drug registration certificate for "Penicillin V Potassium Soluble Powder," which is aimed at treating necrotic enteritis in chickens caused by Clostridium perfringens [1][2]. Group 1: New Veterinary Drug Information - The new veterinary drug is named "Penicillin V Potassium Soluble Powder" and is classified as a Category V drug [1]. - The main ingredient is Penicillin V Potassium, which is indicated for treating necrotic enteritis in chickens caused by Clostridium perfringens [2]. - The recommended dosage is 13.5 to 20 mg per kg of body weight for chickens, to be administered once daily for five consecutive days [1]. Group 2: Market Background and Development - The drug was developed in collaboration with Jinan Lingpai Biological Pharmaceutical Technology Co., Ltd. and has been clinically used abroad for many years, demonstrating safety and high efficacy [2]. - The prevalence of coccidiosis in chickens leads to significant economic losses in the poultry industry, and existing treatments can lead to drug resistance and are often expensive [2]. - Currently, there is no available data on the sales and market share of similar products in circulation [3]. Group 3: Regulatory and Market Impact - Before the product can be marketed, it must obtain a veterinary product approval number from the Ministry of Agriculture and Rural Affairs [4]. - The successful acquisition of the new drug certificate reflects the company's commitment to technological innovation and is expected to enhance its market competitiveness [5].